The Efficacy of Bevacizumab, Sorafenib, and Retinoic Acid on Rat Endometriosis Model

dc.contributor.authorOzer, Hatice
dc.contributor.authorBoztosun, Abdullah
dc.contributor.authorAcmaz, Gokhan
dc.contributor.authorAtilgan, Remzi
dc.contributor.authorAkkar, Ozlem Bozoklu
dc.contributor.authorKosar, Mehmet Ilkay
dc.date.accessioned2026-08-12T17:31:46Z
dc.date.issued2013
dc.departmentFırat Üniversitesi
dc.description.abstractBlood vessels are necessary for development and maintenance of the endometriosis and blood flow supplies oxygen and essential nutrient to the disease. Local angiogenesis is regulated by vascular endothelial growth factor (VEGF) and inhibitors of VEGF may be a novel therapeutic approach. We inducted endometriosis in 43 rats and they were randomly allocated into 4 groups. The rats in group I (control n = 11) were given no medication. The rats in group II (n = 11) were given bevacizumab. The rats in group III (n = 11) were given Sorafenib, and the rats in group IV (n = 10) were given retinoic acid (RA). Then groups were compared for microvessel density, VEGF, soluble tyrosine-kinase receptor, ovarian reserve, and treatment effectivity. All these medications were effective on endometriosis and we detected that volume of endometriotic implants were significantly decreased. Ovarian reserve was not affected from the medication, in addition RA have induced reproductive capacity.
dc.description.sponsorshipCumhuriyet University
dc.description.sponsorshipThe authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Cumhuriyet University financially supported this study.
dc.identifier.doi10.1177/1933719112452941
dc.identifier.endpage32
dc.identifier.issn1933-7191
dc.identifier.issn1933-7205
dc.identifier.issue1
dc.identifier.orcid0000-0002-5773-1838
dc.identifier.pmid22895024
dc.identifier.scopus2-s2.0-84870542388
dc.identifier.scopusqualityQ1
dc.identifier.startpage26
dc.identifier.urihttps://doi.org/10.1177/1933719112452941
dc.identifier.urihttps://hdl.handle.net/11508/56381
dc.identifier.volume20
dc.identifier.wosWOS:000311803000003
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Inc
dc.relation.ispartofReproductive Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectendometriosis
dc.subjectrat
dc.subjecttreatment
dc.titleThe Efficacy of Bevacizumab, Sorafenib, and Retinoic Acid on Rat Endometriosis Model
dc.typeArticle

Dosyalar